Join New York Times columnist David Brooks as he engages the authors of “Brainwashed: The Seductive Appeal of Mindless Neuroscience” Sally Satel and Scott Lilienfeld, in a discussion of popular neuroscience.

At this event, Paul Spitalnic, Medicare’s acting chief actuary, will explain the results of this year’s Medicare trustees report. A panel of experts will then discuss how developments in the health sector will affect Medicare’s long-term future.

Mark Warshawsky, a well-known expert in retirement finance and a newly appointed commissioner, will explain the implications of a publicly funded long-term care insurance program. Then a panel will debate whether another government program the best way to ensure that families can afford to provide the necessary services for their aging loved ones.

The Internal Revenue Service is facing a class action lawsuit alleging that more than 60 million personal medical records were improperly seized by agents from the embattled agency.

So how do you feel about turning over access to some of your most sensitive healthcare information to the Internal Revenue Service?

Fourteen years in the making, the D.S.M.-5 has been the subject of seemingly endless discussion.

There seems to be a surprisingly pervasive belief that drug companies aren't working on cures for disease because it's far more profitable to chronically maintain patients on medication.

Click here to watch Resident Fellow Scott Gottlieb debate the hazards of the FDA on Intelligence Squared U.S. Debates.

The latest mortal threat to Obamacare’s full implementation next January resurfaced last Thursday in the form of a new lawsuit filed in federal district court in the District of Columbia. 

Drug companies -- at least every one that I've worked with -- would like to develop important new medicines that improve health and save lives. That's what gets every industry researcher I know up in the morning, and what keeps them going through the many highs and lows that characterize the scientific process.